Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av Ustekinumab hos pediatriska deltagare med måttligt till allvarligt aktiv Crohns sjukdom (UNITI Jr)

2 juli 2026 uppdaterad av: Janssen Research & Development, LLC

En fas 3-studie av effektivitet, säkerhet och farmakokinetik för Ustekinumab som öppen intravenös induktionsbehandling följt av randomiserat dubbelblind subkutant Ustekinumab-underhåll hos pediatriska deltagare med måttligt till allvarligt aktiv Crohns sjukdom

Syftet med denna studie är att utvärdera effektiviteten av ustekinumab-dosering för att inducera klinisk remission (Global) och för att upprätthålla klinisk remission (US); för att utvärdera säkerhetsprofilen och exponeringen för ustekinumab (farmakokinetik [PK]) hos pediatriska deltagare med måttligt till allvarligt aktiv Crohns sjukdom.

Studieöversikt

Status

Avslutad

Betingelser

Studietyp

Interventionell

Inskrivning (Faktisk)

101

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Brussels, Belgien, 1200
        • Cliniques Universitaires Saint Luc
      • Brussels, Belgien, 1020
        • Universitair Kinderziekenhuis Koningin Fabiola
      • Ghent, Belgien, 9000
        • UZ Gent
      • Jette, Belgien, 1090
        • UZ Brussel
      • Leuven, Belgien, 3000
        • UZ Leuven
    • Delaware
      • Wilmington, Delaware, Förenta staterna, 19803
        • Nemours DuPont Hospital for Children
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30342
        • Children's Center for Digestive Health Care
    • Minnesota
      • Rochester, Minnesota, Förenta staterna, 55905
        • Mayo Clinic
    • New Jersey
      • Morristown, New Jersey, Förenta staterna, 07962
        • Morristown Memorial Hospital
    • North Carolina
      • Charlotte, North Carolina, Förenta staterna, 28207
        • Levine Childrens at Atrium Health
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44106
        • University Hospitals Cleveland Medical Center
    • Pennsylvania
      • Hershey, Pennsylvania, Förenta staterna, 17033
        • Penn State Hershey Children's Hospital
    • Texas
      • Fort Worth, Texas, Förenta staterna, 76104
        • Cook Childrens Medical Center
    • Virginia
      • Fairfax, Virginia, Förenta staterna, 22031
        • Pediatric Specialists Of Virginia
      • Be’er Ya‘aqov, Israel, 70300
        • Yitzhak Shamir Medical Center
      • Haifa, Israel, 34362
        • Carmel Medical Center
      • Jerusalem, Israel, 9103102
        • Shaare Zedek Medical Center
      • Petah Tikva, Israel, 4920235
        • Schneider Children's Medical Center
      • Bunkyō City, Japan, 113 8431
        • Juntendo University Hospital
      • Gunma, Japan, 371-0034
        • Gunma University Hospital
      • Ikoma, Japan, 630-0293
        • Kindai University Nara Hospital
      • Kurume, Japan, 830-0011
        • Kurume University Hospital
      • Saitama Shi, Japan, 330-8777
        • Saitama Childrens Medical Center
      • Sendai, Japan, 989-3126
        • Miyagi Children's Hospital
      • Setagaya Ku, Japan, 157 8535
        • National Center for Child Health and Development
      • Shimotsuke, Japan, 329-0498
        • Jichi Medical University Hospital
      • Tsu, Japan, 514 8507
        • Mie University Hospital
      • Gdansk, Polen, 80 803
        • Szpital im. M. Kopernika
      • Krakow, Polen, 30 663
        • Uniwersytecki Szpital Dzieciecy w Krakowie
      • Rzeszów, Polen, 35-302
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw, Polen, 04 501
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw, Polen, 04 730
        • Instytut Pomnik Centrum Zdrowia Dziecka
      • Kazan', Ryssland, 420138
        • Kazan State Medical University
      • Moscow, Ryssland, 119571
        • Russian National Research Medical University named after N.I.Pirogov
      • Nizhny Novgorod, Ryssland, 603950
        • Privolzhsky Research Medical University of Ministry of Health of Russian Federation
      • Yaroslavl, Ryssland, 150032
        • Yaroslavl Regional Children's Clinical Hospital
      • Birmingham, Storbritannien, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, Storbritannien, BS2 8BJ
        • University Hospitals Bristol and Weston NHS Foundation Trust
      • Cambridge, Storbritannien, CB2 0QQ
        • Cambridge University Hospitals NHS Foundation Trust
      • Edinburgh, Storbritannien, EH16 4TJ
        • Royal Hospital for Children and Young People
      • London, Storbritannien, E1 2AT
        • Royal London Hospital
      • Aachen, Tyskland, 52074
        • Universitätsklinikum Aachen
      • Berlin, Tyskland, 13353
        • Charite-Universitätsmedizin Berlin - Berlin
      • Essen, Tyskland, 45147
        • Universitätsklinikum Essen
      • Hanover, Tyskland, 30625
        • Medizinische Hochschule Hannover
      • Munich, Tyskland, 80337
        • Dr. von Haunersches Kinderspital
      • Regensburg, Tyskland, 93049
        • KUNO Klinik St. Hedwig
      • Ulm, Tyskland, 89075
        • Universitätsklinikum Ulm
      • Budapest, Ungern, 1083
        • Semmelweis Egyetem
      • Debrecen, Ungern, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Miskolc, Ungern, 3526
        • Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
      • Nyíregyháza, Ungern, 4400
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház
      • Szeged, Ungern, 6720
        • Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

2 år till 17 år (Barn)

Tar emot friska volontärer

Nej

Beskrivning

Inklusionskriterier:

  • Har Crohns sjukdom eller fistulerande Crohns sjukdom med aktiv kolit, ileit eller ileokolit, bekräftad när som helst i det förflutna genom endoskopi och histologi
  • Måste ha måttligt till allvarligt aktiv Crohns sjukdom (enligt definitionen av ett baseline Pediatric Crohns Disease Activity Index [PCDAI]-poäng högre än [>] 30); ha ileokolonoskopi med bevis på aktiv Crohns sjukdom definierad som närvaro av sårbildning (vilket är lika med Simple Endoscopic Score för Crohns sjukdom [SES-CD]-poäng större än eller lika med [>=] 3) under screening i denna studie. Ileokolonoskopiproceduren måste ske inom cirka 3 veckor före administrering av studieintervention vid vecka 0 (induktionsperiod). En video-ileokolonoskopi inspelad inom 3 månader före besöket vecka 0 (induktionsperiod) kan användas i fall av ny screening av en deltagare som genomgått en ileokolonoskopi men misslyckades med den initiala screeningen av annan anledning, från fall till fall, efter samråd med sponsorn. Om det inte går att utvärdera sårbildning på grund av striktur eller otillräcklig förberedelse av tarmen, kan åtminstone ett av följande kriterier istället tillämpas: ett onormalt C-reaktivt protein (CRP) (> 0,3 milligram per deciliter [mg/dL] eller 3,0 milligram per liter [mg/L] vid screening) eller; fekalt kalprotektin på >= 250 milligram per kilogram [mg/kg] eller >= 250 mikrogram per gram [mcg/g] vid screening
  • Om du får enteral näring, måste den ha varit på en stabil kur i minst 2 veckor före induktion vecka 0 (vecka I-0)
  • Kvinnor i fertil ålder måste ha ett negativt mycket känsligt uringraviditetstest vid screening och vecka I-0 före administrering av studieintervention

Exklusions kriterier:

  • Har komplikationer av Crohns sjukdom såsom symtomatisk förträngning eller stenos, kort tarmsyndrom eller någon annan manifestation som kan förväntas kräva kirurgi, som kan utesluta användningen av PCDAI för att bedöma respons på terapi eller som möjligen skulle förvirra förmågan att bedöma effekt av behandling med ustekinumab
  • Har en historia av latent eller aktiv granulomatös infektion, histoplasmos eller coccidioidomycosis, eller har haft en icke-tuberkulös mykobakteriell infektion före screening
  • Närvaro eller historia av någon malignitet inklusive närvaro eller historia av lymfoproliferativ sjukdom inklusive lymfom, eller tecken och symtom som tyder på möjlig lymfoproliferativ sjukdom, såsom lymfadenopati av ovanlig storlek eller plats (exempel, noder i den bakre triangeln av halsen, infraklavikulära, epitrokleära, eller periaorta områden), och monoklonal gammopati av obestämd betydelse, eller kliniskt signifikant hepatomegali eller splenomegali
  • Har en historia av måttlig eller svår progressiv eller okontrollerad lever- eller njurinsufficiens; eller betydande hjärt-, kärl-, lung-, gastrointestinala, endokrina, neurologiska, hematologiska, psykiatriska (inklusive suicidalitet) eller metabola störningar
  • Fick en undersökningsintervention inklusive eventuella prövningsvacciner eller använde en invasiv prövningsmedicinsk utrustning inom 3 månader före den planerade första dosen av studieintervention eller är för närvarande inskriven i en undersökningsstudie; mottagande av ett undersökningsvaccin för Coronavirus Disease 2019 (COVID-19) är inte ett automatiskt uteslutningskriterium

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Open-Label Ustekinumab Intravenös (IV): Induktionsperiod
Alla deltagare kommer att få en enda intravenös administrering av ustekinumab vid induktionsvecka 0 (I-0) baserat på kroppsyta (BSA) (milligram per kvadratmeter kvadrat [mg/m^2]) eller viktnivåinduktionsdos (milligram per kilogram [mg/kg]).
Ustekinumab kommer att administreras intravenöst under induktionsperioden och subkutant under underhållsperioden.
Experimentell: Ustekinumab subkutant (SC) var 8:e vecka (q8w): Underhållsperiod
Deltagarna kommer att få SC-administrering av ustekinumab q8w baserat på BSA (mg/m^2) eller viktnivåinduktionsdos (mg/kg) vid underhållsveckorna (veckorna M)-0, M-8, M-16, M-24 , M 32 och M-40 och matchande placebo vid veckorna M-12 och M-36 för att bibehålla blindheten.
Ustekinumab kommer att administreras intravenöst under induktionsperioden och subkutant under underhållsperioden.
Matchande placebo kommer att administreras som subkutan injektion.
Experimentell: Ustekinumab SC var 12:e vecka (q12w): Underhållsperiod
Deltagarna kommer att få SC-administrering av ustekinumab q12w baserat på BSA (mg/m^2) eller viktnivåinduktionsdos (mg/kg) vid veckorna M-0, M-12, M-24, M-36 och matchande placebo kl. Veckorna M-8, M-16, M-32 och M-40 för att underhålla blinden.
Ustekinumab kommer att administreras intravenöst under induktionsperioden och subkutant under underhållsperioden.
Matchande placebo kommer att administreras som subkutan injektion.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 8 (Week I-8)
Tidsram: Induction Week 8 (Week I-8)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: hematocrit [HCT], erythrocyte sedimentation rate [ESR], Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item is assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score =5. For albumin level, the maximum score = 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Induction Week 8 (Week I-8)
US-specific Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44
Tidsram: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Tidsram: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Tidsram: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TESAEs was reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly. TESAEs were defined as any SAE occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With AEs Leading to Discontinuation of Study Intervention
Tidsram: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Number of participants with AEs leading to discontinuation of study intervention were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Global and US-specific Outcome Measures: Number of Participants With AEs of Special Interest (AESI)
Tidsram: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. AESI were defined as any newly identified malignancy, or case of active TB, or opportunistic infection occurring after the first administration of study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
Tidsram: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters (hematology) were reported. It included hemoglobin (Hb). Grades 0-4 were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0 was normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where atleast one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
Tidsram: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters were reported. It included chemistry measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST),blood bilirubin (BB). Grades 0-4 were based on NCI-CTCAE version 5.0, where Grade 0 was Normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where at least one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
Tidsram: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) Injection-Site Reactions (Maintenance Period) were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Serum Ustekinumab Concentrations
Tidsram: Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
Serum ustekinumab concentrations were reported.
Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 6 as Assessed by Short Pediatric Crohn's Disease Activity Index (sPCDAI)
Tidsram: Induction Week 6 (Week I-6)
Clinical remission was defined as a short Pediatric Crohn's Disease Activity Index (sPCDAI) score <=10. The sPCDAI was composed of six components: abdominal pain, stool frequency, patient general well-being, body weight, abdominal examination (abdominal mass and tenderness), and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected clinical remission or minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was calculated only when >=3 of the 6 components were available.
Induction Week 6 (Week I-6)
Global Outcome Measure: Percentage of Participants With Clinical Response at Induction Week 8
Tidsram: Induction Week 8
Assessment of response in children with Crohn's disease was evaluated using the PCDAI. Clinical response was defined as a reduction from baseline of >=12.5 points in the PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history (abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores (weight and height); physical examination scores (abdominal and perirectal disease); and extraintestinal manifestations. Each index item was assigned a severity score of 0 (normal), 5 (mild abnormality), or 10 (severe abnormality). For HCT and ESR, maximum score was 5, and for albumin level, maximum score was 10. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with a resulting score of <=30 on the 0-100 scale.
Induction Week 8
Global and US-specific Outcome Measures: Percentage of Participants With Clinical Response at Induction Week 6 as Assessed by sPCDAI
Tidsram: Induction Week 6
sPCDAI clinical response was defined as reduction from baseline in the sPCDAI score of >=10. The 6-item sPCDAI score ranges from 0 (no disease activity) to 90 (severe disease activity),calculated by summing weighted scores for abdominal pain, stool frequency, general well-being, body weight, abdominal exam, and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was only calculated when >=3 of the 6 components were available.
Induction Week 6
Global Outcome Measure: Percentage of Participants With Endoscopic Response at Maintenance Week 8 as Assessed by Simplified Endoscopic Score-Crohn's Disease (SES-CD)
Tidsram: Maintenance Period Week 8 (Study Week 16)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Period Week 8 (Study Week 16)
Global Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 8
Tidsram: Maintenance Week 8 (Study Week 16)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 8 (Study Week 16)
Global and US-specific Outcome Measures: Percentage of Participants With Endoscopic Response at Maintenance Week 44 as Assessed by SES-CD
Tidsram: Maintenance Week 44 (Study Week 52)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 44
Tidsram: Maintenance Week 44 (Study Week 52)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
Tidsram: Maintenance Period Week 44 (Study Week 52)
Corticosteroid-free remission was defined as PCDAI score of <=10 points and not receiving corticosteroids for at least 90 days prior to Week M-44. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Period Week 44 (Study Week 52)
Global Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44 Who Had Clinical Remission at Induction Week 8
Tidsram: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

6 april 2021

Primärt slutförande (Faktisk)

28 november 2024

Avslutad studie (Faktisk)

3 mars 2025

Studieregistreringsdatum

Först inskickad

14 december 2020

Först inskickad som uppfyllde QC-kriterierna

14 december 2020

Första postat (Faktisk)

17 december 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

30 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 juli 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Andra studie-ID-nummer

  • CR108864
  • 2019-004225-24 (EudraCT-nummer)
  • CNTO1275CRD3004 (Annan identifierare: Janssen Research & Development, LLC)
  • 2023-504978-38-00 (Registeridentifierare: EUCT number)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Datadelningspolicyn för Janssen Pharmaceutical Companies of Johnson & Johnson finns på www.janssen.com/clinical-trials/transparency. Som nämnts på den här webbplatsen kan förfrågningar om åtkomst till studiedata skickas via Yale Open Data Access (YODA) projektwebbplats på yoda.yale.edu

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera